Frank Mottola - 14 Nov 2023 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
SVP, Quality, GMP, Ops, IT
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol
SUPN
Transactions as of
14 Nov 2023
Net transactions value
-$12,744
Form type
4
Filing time
16 Nov 2023, 17:00:06 UTC
Previous filing
16 Mar 2023
Next filing
26 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Options Exercise $18,480 +2,000 +42% $9.24 6,791 14 Nov 2023 Direct F1
transaction SUPN Common Stock Sale $31,224 -1,110 -16% $28.13 5,681 14 Nov 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Employee Stock Option (Right to Buy) Options Exercise $0 -2,000 -100% $0.000000* 0 14 Nov 2023 Common Stock 2,000 $9.24 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes an aggregate of 343 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
F2 Represents the number of shares of common stock sold to cover the exercise price of the employee stock options.
F3 The option vested in four equal annual installments beginning on January 21, 2015.